Equities Analysts Issue Forecasts for KalVista Pharmaceuticals, Inc.’s Q1 2025 Earnings (NASDAQ:KALV)

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) – Equities researchers at Leerink Partnrs issued their Q1 2025 EPS estimates for shares of KalVista Pharmaceuticals in a research report issued to clients and investors on Tuesday, April 16th. Leerink Partnrs analyst J. Schwartz anticipates that the specialty pharmaceutical company will post earnings of ($0.72) per share for the quarter. The consensus estimate for KalVista Pharmaceuticals’ current full-year earnings is ($3.05) per share. Leerink Partnrs also issued estimates for KalVista Pharmaceuticals’ Q2 2025 earnings at ($0.71) EPS, Q3 2025 earnings at ($0.71) EPS, Q4 2025 earnings at ($0.70) EPS and FY2025 earnings at ($2.83) EPS.

Other research analysts have also issued research reports about the stock. Needham & Company LLC reiterated a “buy” rating and set a $35.00 price objective on shares of KalVista Pharmaceuticals in a research note on Thursday, April 11th. HC Wainwright boosted their price objective on shares of KalVista Pharmaceuticals from $16.00 to $24.00 and gave the stock a “buy” rating in a research note on Wednesday, February 14th.

KalVista Pharmaceuticals Stock Up 0.6 %

NASDAQ KALV opened at $11.57 on Thursday. The firm has a market cap of $488.14 million, a PE ratio of -3.67 and a beta of 0.88. The company has a 50 day moving average price of $12.69 and a 200 day moving average price of $11.26. KalVista Pharmaceuticals has a 52 week low of $7.21 and a 52 week high of $16.88.

KalVista Pharmaceuticals (NASDAQ:KALV) last posted its quarterly earnings results on Monday, March 11th. The specialty pharmaceutical company reported ($0.84) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.09).

Institutional Trading of KalVista Pharmaceuticals

Large investors have recently made changes to their positions in the business. SG Americas Securities LLC boosted its holdings in shares of KalVista Pharmaceuticals by 5.1% in the 4th quarter. SG Americas Securities LLC now owns 137,817 shares of the specialty pharmaceutical company’s stock valued at $1,688,000 after acquiring an additional 6,670 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of KalVista Pharmaceuticals by 9.6% in the 3rd quarter. Vanguard Group Inc. now owns 1,732,489 shares of the specialty pharmaceutical company’s stock valued at $16,684,000 after acquiring an additional 151,808 shares during the last quarter. China Universal Asset Management Co. Ltd. purchased a new stake in shares of KalVista Pharmaceuticals in the 4th quarter valued at $49,000. New York State Common Retirement Fund boosted its holdings in shares of KalVista Pharmaceuticals by 1,860.4% in the 3rd quarter. New York State Common Retirement Fund now owns 9,959 shares of the specialty pharmaceutical company’s stock valued at $96,000 after acquiring an additional 9,451 shares during the last quarter. Finally, Strs Ohio purchased a new stake in shares of KalVista Pharmaceuticals in the 3rd quarter valued at $104,000.

Insider Buying and Selling at KalVista Pharmaceuticals

In related news, major shareholder Venrock Healthcare Capital Par purchased 67,546 shares of the business’s stock in a transaction on Monday, January 22nd. The shares were acquired at an average price of $12.55 per share, for a total transaction of $847,702.30. Following the purchase, the insider now owns 4,527,197 shares of the company’s stock, valued at approximately $56,816,322.35. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CFO Benjamin L. Palleiko sold 22,802 shares of the company’s stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $14.11, for a total value of $321,736.22. Following the sale, the chief financial officer now directly owns 187,315 shares of the company’s stock, valued at approximately $2,643,014.65. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Venrock Healthcare Capital Par acquired 67,546 shares of the company’s stock in a transaction dated Monday, January 22nd. The stock was acquired at an average cost of $12.55 per share, for a total transaction of $847,702.30. Following the completion of the acquisition, the insider now directly owns 4,527,197 shares in the company, valued at $56,816,322.35. The disclosure for this purchase can be found here. In the last quarter, insiders have purchased 207,227 shares of company stock worth $2,808,574 and have sold 75,978 shares worth $1,070,918. 12.30% of the stock is currently owned by company insiders.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.